Physician profile
Christopher Michael Basham
NPI 1831160530
$3,908.70
in general payments reported to CMS, 2019-2025
27 companies · $890 in 2025
The $890 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $99.46 · 2021: $160 · 2022: $264 · 2023: $1,076 · 2024: $1,288 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,253.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $884.80 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $817.71 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $503.41 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $247.72 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $200.87 | 2019-2025 | |
| Glaxosmithkline, LLC. | $171.97 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $166.64 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $139.51 | 2019-2025 | Evenity |
| Novartis Pharmaceuticals Corporation | $121.69 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.52 | 2023 | Xifaxan |
| Astellas Pharma US INC | $81.90 | 2023-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $67.62 | 2022-2025 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $67.49 | 2023-2024 | |
| Biohaven Pharmaceuticals, INC. | $53.87 | 2021 | |
| Merck Sharp & Dohme LLC | $31.48 | 2023-2024 | Verquvo, Belsomra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $30.03 | 2024 | Voquezna |
| Allergan, INC. | $28.14 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.90 | 2023 | |
| Corium, LLC | $23.64 | 2023 | Adlarity |
| Teva Pharmaceuticals USA, INC. | $23.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.21 | 2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.51 | 2025 | Caplyta |
| Daiichi Sankyo INC. | $15.74 | 2021 | |
| Esperion Therapeutics, INC. | $14.73 | 2025 | Nexletol |
| Lundbeck LLC | $14.32 | 2023 | Vyepti |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.70 | 2022 | |
| Amarin Pharma, INC. | $13.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Basham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.